Rosuvastatin sodium (formerly S4522; ZD-4522, trade name: Crestor), the sodium salt of Rosuvastatin, is an HMG-CoA reductase inhibitor approved for the treatment of high cholesterol and related conditions such as dyslipidemia, and to prevent cardiovascular disease. It inhibits HMG-CoA reductase with an IC50 of 11 nM in a cell-free assay. Rosuvastatin belongs to the statin class of antihyperliperdemic drugs.
Physicochemical Properties
| Molecular Formula | C22H27FN3O6S.NA. |
| Molecular Weight | 503.5 |
| Exact Mass | 503.15 |
| CAS # | 147098-18-8 |
| Related CAS # | Rosuvastatin Calcium;147098-20-2;Rosuvastatin-d3 sodium;1279031-70-7;Rosuvastatin;287714-41-4;Rosuvastatin-d6 sodium;2070009-41-3;Rosuvastatin-d6 calcium |
| PubChem CID | 23684378 |
| Appearance | White to light yellow solid powder |
| Melting Point | 128-131℃ |
| LogP | 2.147 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 34 |
| Complexity | 773 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.[Na+] |
| InChi Key | RGEBGDYYHAFODH-DHMAKVBVSA-M |
| InChi Code | InChI=1S/C22H28FN3O6S.Na/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;+1/p-1/b10-9+;/t16-,17-;/m1./s1 |
| Chemical Name | sodium;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate |
| Synonyms | Rosuvastatin Sodium; S4522; ZD-4522; trade name: Crestor |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | Rosuvastatin sodium (10 mg/kg, i.p.) prolongs the QTc from 201±1 msec to 210±2 msec in awake and unrestrained guinea pigs [2]. Rosuvastatin (20 mg/kg/day for 2 weeks) significantly lowers very low-density lipoprotein sodium (VLDL) in streptozotocin-induced diabetic rats [4]. |
| References |
[1]. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44. [2]. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78. [3]. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488. [4]. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~496.50 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9861 mL | 9.9305 mL | 19.8610 mL | |
| 5 mM | 0.3972 mL | 1.9861 mL | 3.9722 mL | |
| 10 mM | 0.1986 mL | 0.9930 mL | 1.9861 mL |